Abstract: The invention provides isolated AIF and PPIA binding peptides that disrupt PPIA/AIF complex formation and/or activity and prevent the resulting death of myocardial cells and to pharmaceutical compositions thereof. The invention further provides uses of the isolated peptides in methods of preventing myocardial cell death and/or sudden cardiac death in subject.

Abstract: The invention relates to the use of serum albumin nanoparticles, preferably human, loaded with a cytotoxic drug and decorated on the surface with at least one biological molecule capable of recognising over-expressed or selectively expressed target receptors on the surface of cells, preferably cancer cells, for the treatment or diagnosis of pathologies, preferably cancer pathologies. The at least one biological molecule is anchored to the surface of the nanoparticles by means of a linker and a transamidation (or transglutamination) reaction mediated by the enzyme transglutaminase.

Abstract: The invention relates to serum albumin nanoparticles, preferably human, optionally loaded with a cytotoxic drug, decorated on the surface with at least one biological molecule capable of recognising over-expressed or selectively expressed target receptors on the surface of cells, preferably cancer cells. In particular, the serum albumin nanoparticles (Alb-NP) are decorated with at least one decoration chain comprising: ? a linker, bound to the nanoparticles by means of an —S— thioether bond, and ? at least one biological molecule.

Abstract: The present invention relates to peptides, a composition comprising said peptides and the use thereof as inhibitors of angiogenesis and/or neoangiogenesis. Furthermore, the present invention relates to the use of said peptides and said composition for the treatment of pathologies correlated with an incorrect angiogenesis and/or neoangiogenesis. In particular, in this context reference is made to angiogenesis and/or neoangiogenesis correlated with VEGFR1.

Abstract: The present invention relates to peptides, a composition comprising said peptides and the use thereof as inhibitors of angiogenesis and/or neoangiogenesis. Furthermore, the present invention relates to the use of said peptides and said composition for the treatment of pathologies correlated with an incorrect angiogenesis and/or neoangiogenesis. In particular, in this context reference is made to angiogenesis and/or neoangiogenesis correlated with VEGFR1.

Abstract: A method of measuring Gadd45? expression comprising the step of measuring Gadd45? expression levels in a sample of cells, for example CD 138 expressing cells, obtained from a subject known to have or suspected of having a haematological malignancy. Expression levels may be used in diagnosis, for example of multiple myeloma, in providing a prognosis, for example in a patient having multiple myeloma or in guiding selection of an appropriate treatment agent, especially a treatment agent comprising Gadd45? and or MKK7 inhibitors. Also datasets comprising measured expression levels from multiple subjects.

Abstract: The present invention relates to an optical fiber and a device including the optical fiber. The optical fiber is an optical fiber (1) functionalized with at least one particle (1) of a polymeric gel comprising at least one photosensitive molecule (7) and at least one biomolecule (6), wherein the at least one particle (2) of the polymeric gel is covalently bound to said optical fiber (1).

Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.

Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.

Abstract: The present invention relates to an optical fiber and a device including the optical fiber. The optical fiber is an optical fiber (1) functionalized with at least one particle (1) of a polymeric gel comprising at least one photosensitive molecule (7) and at least one biomolecule (6), wherein the at least one particle (2) of the polymeric gel is covalently bound to said optical fiber (1).

Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.

Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.

Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.

Abstract: Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders.

Abstract: The present invention relates to anti-Nodal antibodies and use of the anti-Nodal antibodies for diagnosing, preventing, and treating a Nodal-related disorder or disease.

Abstract: Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders.

Abstract: Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders.

Abstract: A method of measuring Gadd45? expression comprising the step of measuring Gadd45? expression levels in a sample of cells, for example CD 138 expressing cells, obtained from a subject known to have or suspected of having a haematological malignancy. Expression levels may be used in diagnosis, for example of multiple myeloma, in providing a prognosis, for example in a patient having multiple myeloma or in guiding selection of an appropriate treatment agent, especially a treatment agent comprising Gadd45? and or MKK7 inhibitors. Also datasets comprising measured expression levels from multiple subjects.

Abstract: Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders.

Abstract: The present invention concerns a monomeric or multimeric tripeptide molecule able of inhibiting Cripto signalling in embryonic stem cells, thereby enhancing dopamine specification and differentiation, after transplantation in animal models of Parkinson's disease, as well as reducing tumor formation, and uses thereof.